Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M87,716Revenue (TTM) $M30,390Net Margin (%)44.4Altman Z-Score3.6
Enterprise Value $M102,643EPS (TTM) $10.0Operating Margin %58.0Piotroski F-Score4
P/E(ttm)6.7Beneish M-Score-2.9Pre-tax Margin (%)56.3Higher ROA y-yN
Price/Book4.710-y EBITDA Growth Rate %--Quick Ratio2.1Cash flow > EarningsY
Price/Sales3.05-y EBITDA Growth Rate %53.0Current Ratio2.2Lower Leverage y-yN
Price/Free Cash Flow5.8y-y EBITDA Growth Rate %-8.2ROA % (ttm)25.7Higher Current Ratio y-yN
Dividend Yield %2.9PEG0.1ROE % (ttm)81.1Less Shares Outstanding y-yY
Payout Ratio %19.0Shares Outstanding M1,307ROIC % (ttm)46.2Gross Margin Increase y-yN

Gurus Latest Trades with GILD

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

GILD is held by these investors:



GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MARTIN JOHN CExecutive Chairman 2017-03-01Sell73,333$70.38-4.09view
WILSON GAYLE EDirector 2017-02-23Sell20,365$69.3-2.6view
MARTIN JOHN CExecutive Chairman 2017-02-01Sell73,333$72.57-6.99view
MARTIN JOHN CExecutive Chairman 2017-01-03Sell73,337$73.59-8.28view
MARTIN JOHN CExecutive Chairman 2016-12-01Sell100,000$73.33-7.95view
MADIGAN JOHN WDirector 2016-11-18Sell105,000$74.86-9.83view
Alton Gregg HEVP Comm&Acs ALA, Corp&Med Aff 2016-11-09Sell10,000$79-14.56view
MARTIN JOHN CExecutive Chairman 2016-11-01Sell100,000$73.76-8.49view
MARTIN JOHN CExecutive Chairman 2016-10-03Sell100,000$77.63-13.05view
Alton Gregg HEVP Comm&Acs ALA, Corp&Med Aff 2016-09-22Sell5,000$81.84-17.52view

Quarterly/Annual Reports about GILD:

News about GILD:

Articles On GuruFocus.com
Executive Chairman Slashes Stake in Gilead Sciences Mar 13 2017 
Stocks for Using a Benjamin Graham Value Investing Strategy Mar 13 2017 
10 Low PE Stock Picks for the Enterprising Investor Mar 03 2017 
Jerome Dodson Adds to 9 Positions in 4th Quarter Mar 01 2017 
The S&P 500's Most Undervalued Stocks Feb 27 2017 
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
10 Undervalued Stocks for the Enterprising Investor Feb 16 2017 
Under the Microscope: Gilead's Recent Dividend Increase Feb 15 2017 
Consider Gilead Sciences Feb 14 2017 
Gilead Sciences, Fossil Reach 3-Year Low Prices Feb 12 2017 

More From Other Websites
Gilead’s Hep C Bestseller Faces Patent Dispute (GILD) Mar 27 2017
Gilead hepatitis C drug patent faces European challenge Mar 27 2017
Alphabet, Allergan, Ford: Doug Kass' Views Mar 27 2017
Biotechs Back in the Doghouse After Failed Rally Mar 23 2017
Mylan Receives Tentative Approval from FDA for HIV Therapy Mar 21 2017
British Columbia lists EPCLUSA™ on public drug plan to treat all six genotypes of chronic... Mar 21 2017
Gilead Sciences: Wait, Its Pipeline Isn't Completely Barren? Mar 20 2017
EPCLUSA™, to treat all six genotypes of chronic hepatitis C infection, added to the Liste des... Mar 20 2017
Why Biotech Stock Gilead (GILD) Could Be a Value Trap Mar 20 2017
Jefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now Mar 20 2017
Dividend Stocks Hedge Funds Are Betting On Mar 16 2017
[$$] Celgene Shows Savvy as Gilead Keeps Backsliding Mar 16 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)